
Cambridge Healthtech Institute’s Inaugural
RNA as a Small Molecule Target
Expanding the Boundaries of Druggable Targets
April 17, 2020
RNA molecules are crucial for delivering cellular information and genetic regulation, but until recently, the drug discovery world has emphasized protein drug targets. Our lack of knowledge in RNA biology prevented us from exploring possibilities of RNA drug targets, but with recent advances in technologies, such as sequencing, new therapeutic strategies are being explored. Join us at the Inaugural RNA as a Small Molecule Target symposium, part of Drug Discovery Chemistry, as we discuss methods and tools to identify specific, potent, novel, small molecule binders of RNA.
Preliminary Agenda
OPTIMIZING SMALL MOLECULES FOR RNA TARGETS
Targeting Pre-mRNA Splicing with Small Molecules
Marla Weetall, PhD, Vice President, Pharmacology, PTC Therapeutics
Repurposing Tools for RNA – And What to Consider When Doing It
Jenifer Kaplan, PhD, Scientist II, Biophysics and Assay Development, Arrakis Therapeutics
Targeting Structurally and Functionally Diverse RNAs with Drug-Like Small Molecules
John Schneekloth Jr. (Jay), PhD, Senior Investigator, Chemical Biology Laboratory; Head, Chemical Genetics Section, Center for Cancer Research, National Cancer Institute, NIH
RNA-targeted Small Molecule Synthesis
Amanda E. Hargrove, PhD, Assistant Professor of Chemistry, Assistant Professor of Biochemistry, Duke University
TARGETING RNA-PROTEIN COMPLEXES
Identification of Small Molecules that Promote Exon 10 Skipping in MAPT Pre-mRNA
Martin Pettersson, PhD, Research Fellow, Research Project Leader, Medicinal Chemistry, Pfizer
Discovering Novel RNA Binding Proteins for Small Molecule Drug Discovery
Pramod Pandey, PhD, Principal Scientist, Merck Research Labs Exploratory Science Center
RNA Splicing Modulation… Application to CD33
Tom Chappie, Associate Research Fellow, Pfizer
* The program is subject to change without notice, due to unforeseen reason.
Sponsor updated
Agenda,Sponsor updated